Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells

Pharmacogenetics and Genomics

Volumn 15, Issue 7, 2005, Pages 513-522

  Kameyama, Yoshio ^a,b   Yamashita, Keiko ^a   Kobayashi, Kaoru ^a   Hosokawa, Masakiyo ^a   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Atorvastatin; Cerivastatin; OATP1B1; Pravastatin; Simvastatin; SLCO1B1; SNP

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPLEMENTARY DNA; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; GENE PRODUCT; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN; PROTEIN SLCO1B1 15; PROTEIN SLCO1B1 15 C1007G; PROTEIN SLCO1B1 5; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG CLEARANCE; EMBRYO; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HELA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MYOPATHY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 15 C1007G GENE; SLCO1B1 5 GENE; SLCO1B1 GENE; TANDEM MASS SPECTROMETRY;

EID: 22544454498     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000170913.73780.5f     Document Type: Article

References (19)

1. Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Rel 2002; 78:43-54.
2. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274:17159-17163.
3. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). J Biol Chem 1999; 274:37161-37168.
4. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002; 54:1343-1352.
5. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273:251-260.
6. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276:9626-9630.
7. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120:525-533.
8. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transporting activity among European- and African-Americans. J Biol Chem 2001; 276:35669-35675.
9. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampicin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304:223-228.
10. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304:610-616.
11. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75:455-463.
12. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75:415-421.
13. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302:804-813.
14. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73:554-565.
15. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 2001; 18: 1262-1269.
16. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-440.
17. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 277:43058-43063.
18. Matsuyama K, Nakagawa K, Nakai A, Konishi Y, Nishikata M, Tanaka H, et al. T. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Biol Pharm Bull 2002; 25:346-350.
19. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690.